Scientific, a world leader in the innovation and manufacture of cell
culture media, announced today the addition of three new serum-free
media for the differentiation of mesenchymal stem/stromal cells into
adipogenic, osteogenic, and chondrogenic lineages. These are the newest
in the growing PRIME-XV® line of cell therapy products Irvine
Scientific has developed to provide researchers the highest quality and
performance media for the culture of human stem cells and primary cells.
These media are manufactured under cGMP conditions in ISO13485 certified
facilities to facilitate transition to clinical applications.
"Achieving robust differentiation and cell viability in serum-free media
provides researchers the consistency and quality required for clinical
studies," says Dr. Rebecca Gilbert, R&D Director at Irvine Scientific.
"We are committed to leveraging our expertise in media development to
support rapid growth of cell therapy research."
All three media are supplied in a time-saving, ready-to-use format and
require no mixing of additional components.
About Irvine Scientific
Irvine Scientific, a member of JX Holdings Group, is a worldwide leader
in the innovation and manufacture of cell culture media, reagents, and
medical devices for researchers and clinicians. The company provides
unrivalled service and quality to scientists working in cell therapy and
regenerative medicine, assisted reproductive technology and
cytogenetics, and industrial cell culture for the large-scale production
of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO
and FDA regulations and operates dual cGMP manufacturing facilities in
California, USA and Tokyo, Japan. The company's consultative philosophy
combined with expertise in cell culture and compliance provides
customers with unique capabilities and support. For over 40 years Irvine
Scientific has remained uniquely flexible and focused on media while
becoming a strategic global leader in media products and services.
[ Back To NFVZone's Homepage ]